Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURESTEM-RA in Moderate to Severe Rheumatoid Arthritis
NCT03618784Phase 2Completed
- Sponsor
- Kangstem Biotech
- Start
- Jul 2018
- Primary completion
- Oct 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of FURESTEM-RA in rheumatoid arthritis (RA), sponsored by Kangstem Biotech. Started Jul 2018; status: completed.
02
Drugs
FURESTEM-RA
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03618784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618784.